MaxCyte, Inc. (MXCT)

NASDAQ: MXCT · IEX Real-Time Price · USD
7.77 0.00 (0.00%)
Jan 14, 2022 4:00 PM EST - Market closed
Market Cap785.81M
Revenue (ttm)32.26M
Net Income (ttm)-16.86M
Shares Out101.13M
EPS (ttm)-0.20
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume232,310
Open7.72
Previous Closen/a
Day's Range7.54 - 7.86
52-Week Range7.54 - 17.44
Beta1.04
AnalystsStrong Buy
Price Target19.00 (+144.5%)
Earnings DateNov 10, 2021

About MXCT

MaxCyte is a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past twenty years, we have developed and commercialized our proprietary Flow Electroporation platform, which facilitates complex engineering of a wide variety of cells. Cell therapy has emerged as one of the fastest growing and most promising treatment modalities to address a host of human diseases....

IndustryDiagnostics & Research
IPO DateJul 30, 2021
CEODoug Doerfler
Employees65
Stock ExchangeNASDAQ
Ticker SymbolMXCT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for MaxCyte stock is "Strong Buy." The 12-month stock price forecast is 19.00, which is an increase of 144.53% from the latest price.

Price Target
$19.00
(144.53% upside)
Analyst Consensus: Strong Buy

News

MaxCyte to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., Nov. 12, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to ...

2 months ago - GlobeNewsWire

MaxCyte Reports Third Quarter Financial Results

GAITHERSBURG, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to ...

2 months ago - GlobeNewsWire

MaxCyte Board Member Richard Douglas, PhD, Appointed Chairman of the Board

GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN) is a leading commercial cell-engineering company focused on providing enabling platform technologies t...

2 months ago - GlobeNewsWire

Result of AGM

GAITHERSBURG, Md., Oct. 29, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to ...

2 months ago - GlobeNewsWire

MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs

Nkarta to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its oncology cell-therapy candidates Nkarta to use MaxCyte's Flow Electroporation® technolo...

2 months ago - GlobeNewsWire

MaxCyte to Report Third Quarter 2021 Financial Results on November 10, 2021

GAITHERSBURG, Md., Oct. 25, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to ...

2 months ago - GlobeNewsWire

MaxCyte Set to Join Russell 2000® Index

GAITHERSBURG, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to...

3 months ago - GlobeNewsWire

MaxCyte Reports Second Quarter and Half-Year 2021 Financial Results Provides Preliminary 2021 Revenue Projections

GAITHERSBURG, Md., Sept. 13, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell engineering company focused on providing enabling platform technologies to...

4 months ago - GlobeNewsWire

MaxCyte to Report Second Quarter 2021 Financial Results on September 13, 2021

GAITHERSBURG, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex vivo cell engineering, today announced t...

4 months ago - GlobeNewsWire

MaxCyte Signs Clinical and Commercial License with Sana Biotechnology

GAITHERSBURG, Md., Aug. 9, 2021 /PRNewswire/ -- MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announced the signing of a clinical an...

5 months ago - PRNewsWire

London-Listed MaxCyte Makes NASDAQ Debut Today

MaxCyte Inc (NASDAQ: MXCT) is already trading on London's AIM, but now, it debuted on NASDAQ after pricing a $176 million IPO at $13 apiece, on the higher end of an $11.50 to $13.50 range. The Company o...

5 months ago - Benzinga

DLA Piper advises underwriters of MaxCyte's upsized US IPO

NEW YORK, July 30, 2021 /PRNewswire/ -- DLA Piper represented Cowen and Company, LLC, Stifel, Nicolaus & Company, Incorporated and William Blair & Company, L.L.C., as underwriters in the initial US publ...

5 months ago - PRNewsWire

MaxCyte Announces Pricing of Upsized Offering and Approval to List on the Nasdaq Global Select Market

GAITHERSBURG, Md., July 29, 2021 /PRNewswire/ -- MaxCyte, Inc., (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announced the pricing of its upsized offering of 13...

5 months ago - PRNewsWire

MaxCyte could be valued at more than $1.3 billion as IPO terms have been set

MaxCyte Inc. has set terms for its initial public offering, in which the Maryland-based cell engineering company could be valued at up to $1.31 billion. The company is looking to raise up to $162.0 mill...

5 months ago - Market Watch

MaxCyte Announces Public Filing of Registration Statement with SEC for a Proposed Nasdaq Dual Listing

GAITHERSBURG, Md., July 12, 2021 /PRNewswire/ -- MaxCyte, Inc., (LSE: MXCT) (LSE: MXCN), a leading provider of platform technologies for cell engineering, today announced the public filing of a registra...

6 months ago - PRNewsWire